Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial
Ludwig Kappos, Mark S Freedman, Chris H Polman, Gilles Edan, Hans-Peter Hartung, David H Miller, Xavier Montalbán, Frederik Barkhof, Ernst-Wilhelm Radü, Carola Metzig, Lars Bauer, Vivian Lanius, Rupert Sandbrink, Christoph Pohl, Jette Lautrup Battistini, BENEFIT Study Group
294Citations
(Scopus)
Fingerprint
Dive into the research topics of 'Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial'. Together they form a unique fingerprint.